Affordable Access

Weak Agreement between Antivirogram and PhenoSense Assays in Predicting Reduced Susceptibility to Antiretroviral Drugs

American Society for Microbiology (ASM)
Publication Date
  • Letter To The Editor
  • Biology
  • Medicine


NIAID PACT Pill Brochure HIV­1 A reference guide for prescription HIV-1 medications Several different kinds of antiretroviral drugs are currently used to treat HIV-1 infection. • These medicines do not cure HIV-1 infection or AIDS • These medicines do not eliminate the risk of passing HIV-1 to others • Treatment of HIV-1 infection requires a combination of HIV-1 medicines • Not all medicines are right for all people, and treatments may be different for each person; talk with your doctor or other health care provider if you have questions about your treatment NOTE: Many of these medications pictured may also be available in a generic form, but the generic forms are not pictured here. Tablets and capsules pictured are not actual size. A program of the National Institutes of Health NIH...Turning Discovery into Health® Published by The U.S. Department of Health and Human Services Nucleoside Reverse Transcriptase Inhibitors (NRTIs) NRTIs block reverse transcriptase, an enzyme HIV-1 needs to make copies of itself. Abacavir (ABC) Stavudine (d4T) trade name: Ziagen 300 mg Ziagen tablet trade name: Zerit 15 mg Zerit capsule 20 mg Zerit capsule 30 mg Zerit capsule 20 mg/mL Ziagen oral solution 40 mg Zerit capsule 1 mg/mL Zerit oral solution Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) NNRTIs bind to and alter reverse transcriptase, an enzyme HIV-1 needs to make copies of itself. Efavirenz (EFV) trade name: Sustiva 200 mg Sustiva capsule600 mg Sustiva tablet 50 mg Sustiva capsule Rilpivirine trade name: Edurant 25 mg Edurant tablet Delavirdine trade name: Rescriptor 200 mg Rescriptor tablet 100 mg Rescriptor tablet Nevirapine (NVP) trade names: Viramune Viramune XR 200 mg Viramune tablet 50 mg/5mL Viramune oral suspension Copy of photo used with permission of Boehringer Ingelheim Pharmaceuticals, Inc. VI

There are no comments yet on this publication. Be the first to share your thoughts.